Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4670 - Association of microRNA-21 (miR-21) with efficacy of cetuximab (cet) and bevacizumab (bev) in patients with metastatic colorectal cancer (mCRC) within the FIRE-3 study (AIO KRK-0306)

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Lisa Miller-Phillips

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

L. Miller-Phillips1, L. Fischer von Weikersthal2, F. Kaiser3, S. Al-Batran4, T. Heintges5, D. Neureiter6, C. Kahl7, F. Kullmann8, M. Moehler9, W. Scheithauer10, C. Vazart11, K. Fontaine11, S. Held12, D.P. Modest1, J. Neumann13, A. Jung13, T. Kirchner13, V. Heinemann1, S. Stintzing1

Author affiliations

  • 1 Department Of Medicine Iii, University Hospital, LMU Munich, 81377 - Munich/DE
  • 2 Health Center, Health Center St. Marien, Amberg/DE
  • 3 Studien Gbr, VK&K, Landshut/DE
  • 4 Department Of Hematology And Oncology, Nordwest-Krankenhaus, 60488 - Frankfurt am Main/DE
  • 5 Department Of Medicine Ii, Staedtische Kliniken Neuss, Neuss/DE
  • 6 Institute Of Pathology, Paracelsus Medical University Salzburg, Salzburg/AT
  • 7 Haematology And Oncology, Klinikum Magdeburg, 39130 - Magdeburg/DE
  • 8 Department Of Medicine I, Klinikum Weiden, 92637 - Weiden in der Oberpfalz/DE
  • 9 Department Of Medicine I, Universitiy Hospital, 55131 - Mainz/DE
  • 10 Department Of Internal Medicine I & Comprehensive Cancer Center, Medical University of Vienna, Vienna/AT
  • 11 R&d, IntegraGen SA, 91000 - Evry/FR
  • 12 Statistik, Clinassess, 51379 - Leverkusen/DE
  • 13 Institute Of Pathology, Ludwig Maximilians University, 80337 - Munich/DE
More

Resources

Abstract 4670

Background

FIRE-3 compared first-line therapy with FOLFIRI plus either cet or bev in KRAS exon 2 wildtype (wt) patients with mCRC. Identification of RAS mutations as a predictor for the efficacy of EGFR-antibody therapy raised the question of whether miR-21 as a potential regulator of the EGFR dependent pathway influences therapy outcome.

Methods

A reverse-transcription quantitative polymerase chain reaction (RT-qPCR) assay was used to identify quantitative miR-21 expression in formalin-fixed paraffin-embedded (FFPE) tumor samples of FIRE-3 patients. The median of miR-21 expression within the FIRE-3 population was determined and subsequently used to segment the population into low and high miR-21 expression groups. Overall response rate (ORR) between treatment groups was compared using Fisheŕs exact test. Median progression free (PFS) and overall survival (OS) were calculated using Kaplan-Meier estimation and compared through log-rank test.

Results

RAS wt population with low miR-21 expression (n = 146) showed a significantly higher ORR when cet instead of bev was added to FOLFIRI chemotherapy (80.0% vs. 57.9%; p = 0.005). High miR-21 expression in RAS wt population (n = 149) showed no significant difference in ORR between treatment groups (74.6% vs. 64.0%; p = 0.21). ORR of RAS mutated patients with high miR-21 expression (n = 48) showed no significant difference between cet or bev when added to FOLFIRI (38.1% vs. 59.3%; p = 0.24). ORR (50.0% vs. 48.3%; p > 0.99) also showed no significant difference in RAS mutated patients with low miR-21 expression (n = 59). The following table presents statistical results of PFS and OS by comparing FOLFIRI plus cet versus FOLFIRI plus bev depending on RAS and miR-21 status.Table: 124P

RAS wtRAS mut
low miR-21 (n = 166)high miR-21 (n = 167)low miR-21 (n = 67)high miR-21 (n = 62)
PFS (months)10.6 vs. 10.3 p = 0.310.1 vs. 9.9 p = 0.58.5 vs. 12.2 p = 0.37.7 vs. 8.9 p = 0.044
OS (months)35.8 vs. 25.9 p = 0.00524.5 vs. 23.8 p = 0.420.2 vs. 26.0 p = 0.416.4 vs. 20.2 p = 0.2

Conclusions

Along with RAS status, miR-21 expression level may be a promising predictive biomarker for anti-EGFR-therapy.

Clinical trial identification

NCT00433927; Study Start Date: January 2007; First Posted: February 12, 2007.

Legal entity responsible for the study

University Hospital, LMU Munich.

Funding

Merck.

Editorial Acknowledgement

Disclosure

C. Vazart, K. Fontaine: Employee: Integragen. D.P. Modest: Honoraria and advisory boards: Amgen, Bayer, Merck, MSD, Roche, Servier, Taiho, BMS, Sirtex; Travel support/research funding: Amgen, Bayer, Merck, Roche, Servier. V. Heinemann: Advisory boards: Merck KgaA, Roche AG, Amgen, Sanofi, Lilly, Sirtex, Boehringer Ingelheim, Taiho, Servier; Honoraria for talks: Merck KgaA, Roche AG, Amgen, Sanofi, Sirtex, Servier, MSD; Travel expenses to meetings: Merck KgaA, Roche AG, Amgen, Sirtex, Servier, MSD, BMS; Funding of research activity: Merck KgaA, Pfizer, Amgen, Roche, Servier, Sirtex. S. Stintzing: Honoraria for talks and travel support: Amgen, Bayer, Roche, Merck KgaA, SANOFI, Lilly, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings